researc-dev1

Research & Development

Sanofi Pasteur MSD is proud to be able to draw from two world leading pipelines for its vaccine development and delivery.

  • Sanofi Pasteur MSD Pipeline

    R&D Key developments Registration New Vaccines

    Vaxigrip quadrivalent

    9 valent HPV vaccine (V503)

    Pediatric Hexavalent Vaccine (PR5i)

    ProQuad

    Hexyon (2014)

    Zostavax (2014)

    Sanofi Pasteur pipeline

    Merck  pipeline

    Joint Sanofi Pasteur/Merck development

  • Sanofi Pasteur R&D Pipeline – 13 vaccines in development1

    Phase I Phase II Phase III

    Tuberculosis

    Recombinant subunit vaccine

    Herpes Simplex Virus Type 2 HSV-2 vaccine

    Streptococcus pneumonia

    Meningitis & pneumonia vaccine

    Pseudomonas aeruginosa

    Antibody fragment product. Prevention of ventilator-associated pneumonia

    Meningitis ACYW conj

    2nd generation meningococcal conjugate infant vaccine

    Rabies VRVg

    Purified vero rabies vaccine

    Rotavirus

    Live attenuated tetravalent Rotavirus oral vaccine

    Quadracel®

    Diphtheria, tetanus pertussis  & polio vaccine; 4-y of age

    DTP-HepB-Polio-Hib (PR5I)

    Pediatric hexavalent vaccine

    Dengue

    Mid to severe dengue fever

    Fluzone® QIV ID

    Quadrivalent inactivated influenza vaccine Intradermal

    Vaxigrip® QIV IM

    Quadrivalent inactivated influenza vaccine

    Clostridium difficile

    Toxoid vaccine

    1 source : Sanofi Pasteur Pipeline, February 6th 2014, phase I to III

  • Merck R&D Pipeline1

    Phase II Phase III Under Review

    Pneumoconjugate Vaccine,

    V114

    Pediatric Hexavalent Combination Vaccine,

    V419

    Herpes Zoster Inactivated VZV Vaccine,

    V212

    HPV-Related Cancers

    HPV Vaccine (9 Valent)

    V503 (US)

     

    1 : Source : Merck Pipeline as of April 30, 2014

  • Sanofi Pasteur MSD pipeline
  • Sanofi Pasteur R&D Portfolio
  • Merck R&D Portfolio